PubMed Health⌕ Search

Biomedical subjects

H G Dammann

Publications and source records attributed to H G Dammann.

At least 145 records · Page 8Linked to original sources
PubMed1984

[Comparative study of the effect of famotidine and cimetidine on antipyrine pharmacokinetics in the human].

In a randomized order the pharmacokinetics of antipyrine were studied following a 5 days treatment period with placebo, 1000 mg cimetidine and 40 mg famotidine daily, respectively in 7 healthy volunteers. In contrast to cimetidine, famotidine did not significantly affect the disposition of antipyrine in these subjects. Famotidine like the other guanidino-thiazole containing compound tiotidine appears to be free from this unwanted effect on drug metabolism in the liver.

Adult↗
PubMed1984

Antisecretory and protective properties of prostaglandin analogues in man.

Several prostaglandins inhibit gastric acid secretion and prevent ulcer formation in animals by mechanisms that are independent from each other. Little is known about these properties in humans. The effects of 16,16-dimethyl-prostaglandin E2 and the thiaprostaglandin E2 EMD 33 290 were tested on basal acid secretion as well as on the aspirin- and bile salt-induced fall of gastric transmucosal potential difference in man. 16,16-dm PGE2 and EMD 33 290 prevented the drop in gastric potential difference caused by 1000 mg aspirin or 50 ml of 4 mmol/l Na-taurocholate. The protective doses against aspirin were 0.1 microgram and 50 micrograms for 16,16-dm PGE, and EMD 33 290 respectively. Against Na-taurocholate, doses of 1.0 microgram and 250 micrograms were effective. By contrast, 20-100 times higher doses of both prostaglandin analogues were necessary to inhibit gastric acid secretion. Half maximal inhibition of basal acid output was achieved by 0.1 microgram/kg b.w. of 16,16-dm PGE2 and by 28 micrograms/kg b.w. EMD 33 290. In analogy to animal findings, antisecretory prostaglandins protect the human stomach against aspirin and bile salts in doses which are much smaller than the threshold antisecretory ones.

16,16-Dimethylprostaglandin E2↗
PubMed1984

[4 weeks' administration of omeprazole: effect on acid behavior and basal hormone levels].

We have assessed the effect of omeprazole (30 mg daily) on gastric acid secretion as well as on basal hormone levels (fasting gastrin; TSH, T3, T4, TBG; insulin, glucagon, C-peptide; prolactin, testosterone, 17-beta-oestradiol, dihydroepiandrosterone, cortisol and PTH) in 8 healthy volunteers before and after a 28 day treatment. On day 29, i. e. one day after the last omeprazole dose, mean stimulated acid output was still reduced from 27.4 +/- 3.5 mmol H+/h (+/- SEM) to 7.8 +/- 1.4 mmol H+/h (72% inhibition). Fasting gastrin levels were raised from 55.5 +/- 6.8 pg/ml to 80.9 +/- 6.7 pg/ml (33% increase). On day 39, stimulated gastric acid secretion and fasting gastrin levels have been returned to pretreatment values. Basal levels of prolactin, testosterone, TSH, T3, T4, TBG, cortisol, PTH, 17-beta-oestradiol, insulin, glucagon, c-peptide, dihydroepiandrosterone remained unchanged by a 28-day omeprazole treatment. Omeprazole is a highly effective antisecretory compound without any effect on the basal hormone levels tested. Even after 28 days its effect on acid secretion and fasting gastrin levels was fully reversible.

Adult↗
PubMed1983

[Behavior of acid secretion under the long-term daily administration of omeprazol].

The effect of the substituted benzimidazole omeprazole on acid secretion after repeated administration to healthy volunteers has been studied. During repeated dosage of 30 mg once daily inhibition of basal and pentagastrin-stimulated acid output was increased from 30% after the first dose to about 60% after dose 4. The extent of inhibition did not further increase between day 5 and day 10. In four volunteers acid secretion returned to predose levels within 5 days after drug withdrawal. The 24-hour gastric acidity was reduced by about 72% and 82% after 9-day pretreatment with 30 mg and 60 mg omeprazole respectively. The antisecretory effect of omeprazole was independent of peak plasma concentrations. Omeprazole given once daily therefore possesses a long-lasting effect on gastric acid secretion, i.e. for more than 24 hours. This effect appears to be fully reversible since control levels of acid output are reached within 5 days.

Adult↗
PubMed1983

[Inhibition of basal acid secretion by trimethyldesoxy-prostaglandin E2 in humans].

The effect of graded oral doses of trimethyldesoxy-prostaglandin E2 (Ro 21-6937) on basal acid secretion in healthy volunteers was tested over a time period of 6 h. Basal acid output was reduced by 80% after 1500 micrograms Ro 21-6937. Half-maximal inhibition was achieved by 700 micrograms Ro 21-6937. 250 micrograms of this prostaglandin E2 analog showed no detectable antisecretory activity.

Adult↗
PubMed1983

[Suppression of acid secretion and plasma level of a once-daily dose of omeprazole].

The effect of 5-methoxy-2-[( (4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulphinyl)-1H- benzimidazole (omeprazole) on gastric acid secretion after repeated administration to healthy volunteers has been studied. Omeprazole in a dose of 30 mg given once daily for nine days suppressed acid secretion continuously, the inhibitory effect stabilising after five days. Omeprazole was absorbed and rapidly cleared from plasma; the inhibitory effect was related to the area under the plasma concentration-time curve.

Adult↗
PubMed1983

[Cytoprotection with antacids?].

Prostaglandins in very low concentrations which do not inhibit acid secretion protect the mucosa of the gastrointestinal tract against a great number of noxious agents. The protective action of various antacids is likely to be related to its acid neutralizing capacity. Antacids do not prevent lesions evoked by direct necrotising substances such as concentrated ethanol etc. It remains to be established whether the endogenous prostaglandin system is involved in the antiulcerogenic action of some antacids.

Animals↗
PubMed1982

[Human acid inhibition and prevention of a drop in the transmucosal potential difference by thioprostaglandin EMD 33290].

The effect of graded doses of EMD 33290 on basal acid secretion in healthy volunteers was tested over a time period of 6 hours. In addition, studies were conducted to determine if pretreatment with this thioprostaglandin could prevent the characteristic fall in human gastric potential difference associated with intragastric instillation of 1,000 mg aspirin or of 50 ml 4 mmol/l sodium taurocholate. Basal acid output was reduced by 65% and 75% after a 2 and 3 mg single dose of EMD 33290 respectively. 1 mg of this prostaglandin E2 analog showed no detectable antisecretory activity. EMD 33290 in a single dose of 50 micrograms and 250 micrograms effectively protected human gastric mucosa against the injurious effects of aspirin and sodium taurocholate. It is therefore concluded that EMD 33290 has two distinct properties in the human stomach, viz. antisecretory and protective, which are independent of each other.

Adult↗
PubMed1982

[Newly developed H2-receptor antagonists in the treatment of peptic ulcer disease].

Ranitidine and oxmetidine are newly developed histamine H2-receptor antagonists without any antiandrogenic activity and probably without drug interactions. In numerous clinical trials ranitidine has been proven to be at least as effective as cimetidine in the short- and long-term treatment of peptic ulcer disease. Ranitidine was found to be remarkably safe. Its therapeutic use in man should not be associated with significant adverse reactions.

Biological Availability↗